Tuesday, September 27, 2016

Monsanto Bought Out

Monsanto has accepted Bayer AG’s $66 billion takeover offer, which will make the new entity the largest seed and pesticide company in the world.

If the merger goes through, we’ll be left with just four companies providing 59 percent of the global seeds and 64 percent of the world’s pesticides, which some predict will be a disaster for the global food system.

Wednesday, September 21, 2016

Friday, September 16, 2016

Splenda Naturals: Here We Go!

Due to declining sales of their flagship artificial sweetener, Splenda has produced a rival to Truvia and PureVia.

It has the same ingredients as the other two: stevia extract and erythritol.

They market it as a natural non-caloric sweetener, but as you know now, erythritol is anything but natural.


Don't buy into the hype! 

Thursday, September 15, 2016

Huge Lancet Review on Statins Littered With Conflict of Interest

There was a ton of press on statins a few weeks ago. Take any of it with a grain of salt. Look at the conflict of interest with the authors of the study!


"Declaration of interests from the authors

JA, CB, LB, RC, JE, RP, DP, and CR work in the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford. The CTSU has received research grants from Abbott, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Schering, and Solvay that are governed by University of Oxford contracts that protect its independence, and it has a staff policy of not taking personal payments from industry (with reimbursement sought only for the costs of travel and accommodation to attend scientific meetings). RC is co-inventor of a genetic test for statin-related myopathy risk, but receives no income from it. DP has participated in advisory meetings for Sanofi related to PCSK9 inhibitor therapy in his previous employment. The CTT Collaboration, which is coordinated by CTSU with colleagues from the University of Sydney, does not receive industry funding. JD has received research grants from, and served as a consultant to, Merck and Pfizer. GDS has twice received travel and accommodation funding and honoraria from Merck; DD receives compensation for serving on data monitoring committees for clinical trials (including of statins) funded by Abbvie, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sanofi, and Teva. NW and ML are inventors of a combination formulation for the prevention of cardiovascular disease that includes a statin, covered by patents licensed to Polypill in which they both hold shares and which owns the website polypill.com. SMac has received research grants for research on statins and polypill development from Bristol-Myers Squibb and BUPA. SMar is co-inventor on a pending patent for a LDL cholesterol estimation method, and has served as an advisor to Sanofi, Regeneron, Quest Diagnostics, Pressed Juicery, and Abbott Nutrition. NP has received research grants and honoraria for participating in advisory meetings and giving lectures from Amgen, Lilly, Menorini, and Merck. PR has received investigator-initiated research grants from Amgen, AstraZeneca, Kowa, Novartis, and Pfizer. PSe has received research grants and honoraria for consultancies from Amgen and Pfizer. LS has undertaken advisory work unrelated to statins for AstraZeneca and GlaxoSmithKline. SY has received a research grant from AstraZeneca through Hamilton Health Sciences. AR declares that George Health Enterprises, the social enterprise arm of The George Institute, has received investment to develop combination products containing statin, aspirin, and blood-pressure-lowering drugs. JS has received grants from the National Health and Medical Research Council, Australia; Bayer Pharmaceuticals; Roche; and Merck Serono. RB, SE, BN, IR, and PSa declare no competing interests."

Prostate Cancer: Watchful Waiting Does Not Up Death Risk in Older men


Yucky Federal GMO Bill Becomes Law

Aside from overriding state and local laws, what are some of the DARK Act’s other fundamental deficiencies?

  • There is no requirement for on-package labeling of GMO foods.
  • As many as 100 million Americans lack the ability to find out product specifics by not being able to access QR codes.
  • The biotech-friendly USDA – not the FDA – is charged with creating the law’s actual labeling rules over the next two years.
  • The bill leaves totally unclear what will be considered a GMO food and/or ingredient. According to the FDA, most foods typically thought of as being produced or made with GMO ingredients will not be covered by the bill’s narrow definition of genetic engineering. The USDA might raise the threshold for incidental GMO contamination from the currently accepted .09% to as high as 30% while still calling that non-GMO!
  • The bill suggests that the USDA harmonize its ultimate definition of genetic engineering with the organic law’s definitions – something that could create a huge loophole into organic’s current strict prohibitions on GMO technology.